FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety.
- DOI
- 10.1007/s12029-025-01287-9
- Published
- 2025 Aug 16
- Container
- Journal of gastrointestinal cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12029-025-01287-9,
title = {FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety.},
author = {Khan AM and Muddu VK and Bonda NA and Siripurapu I and Ahmed R and Takreem S and Shahnoor SS and Noor S and Krishnaiah S and Rao GV and Reddy DN},
year = {2025},
journal = {Journal of gastrointestinal cancer},
doi = {10.1007/s12029-025-01287-9},
url = {https://doi.org/10.1007/s12029-025-01287-9}
}RIS
TY - JOUR TI - FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety. AU - Khan AM AU - Muddu VK AU - Bonda NA AU - Siripurapu I AU - Ahmed R AU - Takreem S AU - Shahnoor SS AU - Noor S AU - Krishnaiah S AU - Rao GV AU - Reddy DN PY - 2025 JO - Journal of gastrointestinal cancer DO - 10.1007/s12029-025-01287-9 UR - https://doi.org/10.1007/s12029-025-01287-9 ER -
APA
AM, K., VK, M., NA, B., I, S., R, A., S, T., SS, S., S, N., S, K., GV, R., & DN, R. (2025). FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety.. Journal of gastrointestinal cancer. https://doi.org/10.1007/s12029-025-01287-9
Source records
- pubmed · retrieved 2026-09-25T12:49:13.233Z